References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCommentary: osteoarthritis of the knee and glucosamine
Altman, R. D.; Abramson, S.; Bruyère, Olivier ULg et al

in Osteoarthritis and Cartilage (2006), 14(10), 963-966

Detailed reference viewed: 81 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study
Bruyère, Olivier ULg; Collette, Julien ULg; Kothari, M. et al

in Annals of the Rheumatic Diseases (2006), 65(8), 1050-1054

Objective: To investigate the relation between biochemical markers of bone, cartilage, and synovial remodelling and the structural progression of knee osteoarthritis. Methods: 62 patients of both sexes ... [more ▼]

Objective: To investigate the relation between biochemical markers of bone, cartilage, and synovial remodelling and the structural progression of knee osteoarthritis. Methods: 62 patients of both sexes with knee osteoarthritis were followed prospectively for one year. From magnetic resonance imaging ( MRI), done at baseline and after one year, the volume and thickness of cartilage of the femur, the medial tibia, and the lateral tibia were assessed. A whole organ magnetic resonance imaging score ( WORMS) of the knee was calculated for each patient at baseline and at the one year visits. This score consists in a validated, semiquantitative scoring system for whole organ assessment of the knee in osteoarthritis using MRI. Biochemical markers ( serum hyaluronic acid, osteocalcin, cartilage glycoprotein 39 ( YKL-40), cartilage oligomeric matrix protein ( COMP), and C-telopeptide of type I collagen ( CTX-I), and urine C-telopeptide of type II collagen ( CTX-II)) were measured at baseline and after three months. Results: Baseline markers were not correlated with one year changes observed in cartilage volume and thickness. However, an increase in CTX-II after three months was significantly correlated with a one year decrease in mean thickness of medial tibial and lateral tibial cartilage. Patients in the highest quartile of three month changes in CTX-II experienced a mean loss of 0.07 ( 0.08) mm of their medial thickness, compared with a mean increase of 0.05 ( 0.19) mm for patients in the lowest quartile ( p = 0.04) Multiple regression analysis showed that high baseline levels of hyaluronic acid are predictive of a worsening in WORMS ( p = 0.004). Conclusions: These results suggest that a single measurement of serum hyaluronic acid or short term changes in urine CTX-II could identify patients at greatest risk of progression of osteoarthritis. [less ▲]

Detailed reference viewed: 39 (6 ULg)
Full Text
Peer Reviewed
See detailClinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and Mazzuca
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg; Giacovelli, Giampaolo et al

in Arthritis and Rheumatism (2006), 54(7), 2339-2341

Detailed reference viewed: 14 (6 ULg)
Full Text
Peer Reviewed
See detailSelf-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage
Richy, Florent; Bruyère, Olivier ULg; Maassen, P. et al

in Osteoporosis International (2006, June), 17(Suppl.2), 45-46

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailYoung postmenopausal women have high prevalence of inadequate serum vitamin D levels: results of a European study
Bruyère, Olivier ULg; Malaise, Olivier; Neuprez, Audrey ULg et al

in Osteoporosis International (2006, June), 17(Suppl.2), 56

Detailed reference viewed: 25 (3 ULg)
Full Text
Peer Reviewed
See detailHigh prevalence of inadequate serum vitamind D levels in osteoporotic European postmenopausal women
Bruyère, Olivier ULg; Malaise, Olivier; Neuprez, Audrey ULg et al

in Osteoporosis International (2006, June), 17(Suppl.2), 33-34

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailPrescription and coprescription patterns of bone-active substances among postmenopausal women
Richy, Florent; Bruyère, Olivier ULg; Mawet, Audrey ULg et al

in Osteoporosis International (2006, June), 17(Suppl.2), 60

Detailed reference viewed: 7 (3 ULg)
Full Text
Peer Reviewed
See detailStrontium Ranelate normalizes bone mineral density in osteopenic patients
Malaise, Olivier; Bruyère, Olivier ULg; Deroisy, Rita ULg et al

in Osteoporosis International (2006, June), 17(Suppl.2), 103

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailAssessment of structure-modifying drugs in osteoarthritis: surrogate or hard clinical end points?
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Future Rheumatology (2006), 1(2), 199-206

Current regulatory requirements for the development of disease-modifying drugs in osteoarthritis (OA) still consider the measurement of joint space narrowing (a change in joint space width over many years ... [more ▼]

Current regulatory requirements for the development of disease-modifying drugs in osteoarthritis (OA) still consider the measurement of joint space narrowing (a change in joint space width over many years) on plain x-rays as the appropriate primary end point for the demonstration of efficacy. However, other outcomes have recently been proposed. Among these, time to joint replacement appears to be an attractive option. Preliminary results are encouraging; however, more data are needed before recommending joint replacement as a primary outcome in disease-modifying OA drugs. It should be acknowledged that, owing to potential biases (e.g., absence of recommended guidelines, socio–economic and gender disparities in the rates of knee surgery, variability from country to country and willingness of patients to undergo the surgery), a recent expert consensus panel did not recommend this particular outcome as the primary end point for assessing the success or failure of a disease-modifying drug. Other tools, such as magnetic resonance imaging or biochemical markers, have potential as outcome measures but more studies are needed. [less ▲]

Detailed reference viewed: 33 (11 ULg)
Full Text
Peer Reviewed
See detailActivite antalgique de la glucosamine dans l'arthrose: quoi de neuf en 2006?
Reginster, Jean-Yves ULg; Richy, F.; Bruyère, Olivier ULg

in Revue Médicale de Liège (2006), 61(3), 169-72

Glucosamine is widely used as a symptom-modifying drug in osteoarthritis. New clinical trials, from Europe and the United-States bring some clarification regarding the optimal formulation and doses to be ... [more ▼]

Glucosamine is widely used as a symptom-modifying drug in osteoarthritis. New clinical trials, from Europe and the United-States bring some clarification regarding the optimal formulation and doses to be used in knee osteoarthritis. Their results are supported by new pharmacokinetic and preclinical studies, explaining the mode of action of glucosamine in osteoarthritis. [less ▲]

Detailed reference viewed: 77 (2 ULg)
Full Text
Peer Reviewed
See detailRelations between increase in femoral neck bone mineral density and decrease in hip fracture incidence during treatment with strontium ranelate
Bruyère, Olivier ULg; Delmas, Pierre D; Devogelaer, Jean-Pierre et al

in Osteoporosis International (2006, March), 17(Suppl.1), 96

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailLongitudinal study of magnetic resonance imaging and fixed-flexion radiography to assess progression of osteoarthritis of the knee
Bruyère, Olivier ULg; Kothari, M.; Peterfy, C. et al

in Osteoporosis International (2006, March), 17(Suppl.1), 85

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailCalcium daily food intake in European post-menopausal women
Bruyère, Olivier ULg; Malaise, Olivier; Neuprez, Audrey ULg et al

in Osteoporosis International (2006, March), 17(Suppl.1), 101

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailEarly postmenopausal women have high prevalence of inadequate serum vitamin D levels. Results of a European study
Bruyère, Olivier ULg; Malaise, Olivier; Neuprez, Audrey ULg et al

in Osteoporosis International (2006, March), 17(Suppl.1), 85-86

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailSelf-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage
Richy, Florent; Bruyère, Olivier ULg; Maassen, P. et al

in Osteoporosis International (2006, March), 17(Suppl.1), 93-94

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailOne-year increase in hip (hip or femoral neck) bone mineral density pridicts long-term (3 years) decrease in vertebral fracture incidence in patients treated with strontium ranelate
Bruyère, Olivier ULg; Fardellone, P.; Kaufman, Jean-Marc et al

in Osteoporosis International (2006, March), 17(Suppl.1), 96

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailPrescription and coprescription patterns of bone-active substances among postmenopausal women
Richy, Florent; Bruyère, Olivier ULg; Mawet, Audrey ULg et al

in Osteoporosis International (2006, March), 17(Suppl.1), 93

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailHigh prevalence of inadequate serum vitamind D levels in osteoporotic European postmenopausal women
Bruyère, Olivier ULg; Malaise, Olivier; Neuprez, Audrey ULg et al

in Osteoporosis International (2006, March), 17(Suppl.1), 86

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailStrontium Ranelate normalizes bone mineral density in osteopenic patients
Malaise, Olivier; Bruyère, Olivier ULg; Deroisy, Rita ULg et al

in Osteoporosis International (2006, March), 17(Suppl.1), 63

Detailed reference viewed: 10 (0 ULg)